31 Jan Stem Cells Reported to Improve Vision
UCLA researchers announce improvement in 2 patients receiving stem cell transplants for retinal eye diseases; macular degeneration and Stargardt's Disease....
UCLA researchers announce improvement in 2 patients receiving stem cell transplants for retinal eye diseases; macular degeneration and Stargardt's Disease....
The FDA approved Eylea as a new treatment for wet macular degeneration. Recent reports indicate the drug is similar to Lucentis after the initial year of treatment. Why is this bad news?...
The FDA just approved yet another anti-VEGF treatment for wet macular degeneration. This one does not require monthly injections....
The first implantable telescope for patients with macular degeneration is now available for those eligible patients. Medicare will endorse as of October, 2011....
VEGF Trap Eye is another anti-VEGF medication to be injected into the eye for the treatment of wet macular degeneration. The FDA did not approve recently, but will reconsider by November!...
Clinical trials for RPE replacement therapy for Stargardt's disease and dry AMD have begun. The study will assess the safety of replacing stem-cell derived RPE cells in humans....
Though the FDA upheld its decision no longer approve Avastin for the treatment of breast cancer. The drug is still available for eye patients....
CATT trial revealed that it appears Avastin is as effective as Lucentis for the treatment of wet ARMD. They are equally safe, too....
Avastin injections for wet ARMD are as good as Lucentis. Recent study by the NEI shows the two drugs are equally effective for treating this blinding disease....
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received "priority review" status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10 month period....